Cart
sales@molnova.com
CPI203
CAS No. 1446144-04-2
CPI203( TEN 010 | JQ-2 | RG-6146 )
Catalog No. M11893 CAS No. 1446144-04-2
CPI 203 (TEN 010, JQ-2, RG-6146) is a primary amide analog of (+)-JQ1and a BET bromodomain inhibitor that shows cytotoxicity against MCL cell lines with GI50 of 0.1-0.3 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 54 | In Stock |
|
| 5MG | 97 | In Stock |
|
| 10MG | 155 | In Stock |
|
| 25MG | 332 | In Stock |
|
| 50MG | 499 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCPI203
-
NoteResearch use only, not for human use.
-
Brief DescriptionCPI 203 (TEN 010, JQ-2, RG-6146) is a primary amide analog of (+)-JQ1and a BET bromodomain inhibitor that shows cytotoxicity against MCL cell lines with GI50 of 0.1-0.3 uM.
-
DescriptionCPI 203 (TEN 010, JQ-2, RG-6146) is a primary amide analog of (+)-JQ1and a BET bromodomain inhibitor that shows cytotoxicity against MCL cell lines with GI50 of 0.1-0.3 uM; synergizes the antitumor activity of lenalidomide in bortezomib-resistant mantle cell lymphoma; also enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors, overcomes resistance to ABT-199 (Venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
-
In Vitro——
-
In Vivo——
-
SynonymsTEN 010 | JQ-2 | RG-6146
-
PathwayChromatin/Epigenetic
-
TargetBromodomain
-
RecptorBRD4
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1446144-04-2
-
Formula Weight399.897
-
Molecular FormulaC19H18ClN5OS
-
Purity>98% (HPLC)
-
SolubilityDMSO: 72 mg/mL (180 mM); Ethanol: 5 mg/mL (12.5 mM); Water: <1 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESO=C(N)C[C@H]1C2=NN=C(C)N2C3=C(C(C)=C(C)S3)C(C4=CC=C(Cl)C=C4)=N1
-
Chemical Name(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Moros A, et al. Leukemia. 2014 Oct;28(10):2049-59.
2. Wong C, et al. Cell Death Dis. 2014 Oct 9;5:e1450.
3. Siegel MB, et al. Oncotarget. 2015 Aug 7;6(22):18921-32.
4. Esteve-Arenys A, et al. Oncogene. 2018 Jan 22. doi: 10.1038/s41388-017-0111-1.
molnova catalog
related products
-
LP99
LP99 is the first potent and selective BRD7/9 bromodomain inhibitor with Kd of 99 nM for BRD9; inhibits IL‐6 secretion from THP‐1 cells in a dose‐dependent manner.
-
biBET
biBET is a potent, selective, bivalent inhibitor of BET bromodomains.
-
CD 161
A potent, selective, orally bioavailable BET bromodomain inhibitor with IC50 of 7.2 and 28.2 nM for BRD4 BD2 and BRD4 BD1, respectively.
